Findings seen for patients with type 2 diabetes during a 5-year period. (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...

TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

Dizziness is a frequent and challenging symptom in patients with posterior ischemic stroke, often making it difficult to distinguish from ... Each patient underwent vHIT in addition to the standard ...

Individual patients’ data were pooled from two Chinese multicenter observational studies: the BASILAR (EVT for Acute Basilar Artery Occlusion Study) and the PERSIST (Posterior Circulation Ischemic ...

TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec.

(HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study ...

However, doctors in India say the data is still insufficient to prove that the drug will almost always trigger this condition, called non-arteritic anterior ischemic optic neuropathy (NAION). Should ...

The types of clinical signs seen in the posterior segment of the eye ... AION, anterior ischemic optic neuropathy; BRAO, branch retinal artery occlusion; CWS, cotton-wool spots; ESR, erythrocyte ...